Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
April 27, 2022 at 05:30 pm IST
Share
Harbin Pharmaceutical Group Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 3,333.84 million compared to CNY 2,979.9 million a year ago. Revenue was CNY 3,333.84 million compared to CNY 2,979.9 million a year ago. Net income was CNY 100.45 million compared to CNY 82.87 million a year ago. Basic earnings per share from continuing operations was CNY 0.04 compared to CNY 0.03 a year ago. Diluted earnings per share from continuing operations was CNY 0.04 compared to CNY 0.03 a year ago.
Harbin Pharmaceutical Group Co is a China-based company mainly engaged in pharmaceutical research and development. The Company's main businesses are innovative research and development in high-tech fields such as antibiotics, modern Chinese medicine, and biopharmaceuticals, covering the business sectors of antibiotics, over-the-counter drugs and health products, traditional and modern Chinese medicine, biomedicine, and pharmaceutical commerce. The Companyâs main products include calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, alprostadil injection, pediatric paracetamol Huangnamin granules, lacidipine tablets, hydrochloric acid for injection Cefotiam, ibuprofen granules, Xingaizhonggai high calcium tablets, etc.